![](https://investorshub.advfn.com/uicon/564105.png?cb=1547105359)
Monday, April 15, 2019 7:02:12 AM
Please consider that a system that has ONE indication - lung biopsy - just sold for billions of dollars. That's enough to make a lot of investors happy, if we went for the same price as Auris (personally, I want more and think Titan is worth more).
This alone should address concerns about both issues, but we also have a predicate device showing how easily our technology will expand to a plethora of additional indications, and any organization interested in buying a robotic surgical system will be keenly aware of this.
I know, the counter-argument will be that we don't have FDA approval... Not worried about that either; the schedule is known; they are working closely with the FDA to prevent any surprises, and the predicate device will help ensure smooth sailing to approval. And I'm not expecting Titan to be sold next week; we can wait for approval.
No worries!
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM